Skip to main content
Premium Trial:

Request an Annual Quote

GNS Healthcare Nets $10M in Series B Financing

NEW YORK (GenomeWeb News) — GNS Healthcare has reeled in $10 million in financing that it will use to expand its data analytic business more broadly across the healthcare industry.

The series B financing included participation from previous investor Cambia Health Solutions and from California's Heritage Provider Network and Mitsui and Co., Cambridge, Mass.-based GNS Healthcare said yesterday.

The company uses big data analytics to develop models and products for predicting the effects that health interventions will have for individual patients. Pharmaceutical firms, health plans, and providers use these models to discover biomarkers that predict patient responses to medications, predict individual and population risks and costs, and provide comparative-effectiveness analysis.

"The market potential for big data is huge, as it will radically change how we develop, pay for, and utilize therapies and other interventions for patients," Masahiro Moriyasu, senior VP at Mitsui USA, said in a statement.

GNS Healthcare's REFS platform is a supercomputer-enabled framework that "automates the discovery of causal models from observational and experimental data and uses high-throughput simulations to generate new knowledge," the company said.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.